Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the "Shock and Kill" Approach
Based on a growing body of data demonstrating apabetalone's beneficial attributes as a latency-reversing agent for advancing HIV-1 eradication, Resverlogix is seeking a partner for future development
CALGARY, Alberta and BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Based on recent findings on apabetalone's potential role in human immunodeficiency virus ("HIV-1") eradication, Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is seeking a partnership with an existing stakeholder in the ongoing fight against HIV-1. The most recent publication titled: "The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation," in Nature's Acta Pharmacologica Sinica (2018) 0:1-13; demonstrated apabetalone's abilities to expose and reactivate latent HIV-1 reservoirs, induce HIV-1 latent cell death, and reduce the side effects of standard of care (cART combination antiretroviral therapy).
"Bromodomain and extra-terminal (BET) proteins play a role in maintaining HIV-1 in latent cell reservoirs inaccessible to anti-viral agents. The virus hiding within the cells is the primary reason for treatment failure and the inability to fully eliminate the virus from a patient. Treatment with the BD2 selective BET inhibitor apabetalone results in the activation and release of the virus from the cells, allowing it to be targeted for eradication by concurrent anti-viral therapy," stated Ewelina Kulikowski, Senior Vice President of Research and Development.
"Apabetalone's unique epigenetic mechanism of action has once again been tied to another important grievous disease for which there is no cure. In order to help expedite development in this space, interested HIV/AIDS stakeholders such as patient advocacy groups, government health bodies, major phamaceutical companies, and/or non-government research organization (NRO's) are encouraged to contact Resverlogix to further the research and development of apabetalone as a therapeutic for HIV-1 eradication," stated Donald McCaffrey, President & CEO of Resverlogix.
Resverlogix continues the development of apabetalone in high-risk CVD patients with type 2 diabetes mellitus and low levels of high-density lipoprotein (HDL), as well as in chronic kidney disease and Fabry disease.
About HIV & HIV Latency
According to the UNAIDS foundation there was an estimated 36.7 million people living with HIV globally in 2016, of which 20.9 million people were estimated to be accessing HIV antiretroviral therapy by June 2017. The treatment for HIV is a lifelong process requiring continuous medication. Reducing the frequency with which medication needs to be taken would not only improve quality of life and adherence to therapies, but also decrease the economic burden associated with HIV treatment. Latent HIV-1 reservoirs are the main cause of treatment failure. Latency reversal agents (LRAs) which would deplete latent HIV reservoirs, in conjunction with combination anti-retroviral agents, would allow for effective killing and eradication of HIV.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have chronic kidney disease.
The Company's kidney program is assessing apabetalone's effect in non-dialysis patients as well as in patients on dialysis with the eventual objective of addressing the huge medical need and demonstrate improved health outcomes.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to, and the potential role of apabetalone in the treatment of HIV-1, AIDS, CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resverlogix Corp via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
WillScot Announces Closing of Warrant Exchange Offer11.12.2018 22:05 | Pressemelding
BALTIMORE, Dec. 11, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced the closing of its previously announced exchange offer (the “Exchange Offer”) relating to certain outstanding warrants issued in 2015 (the “Warrants”). Under the terms of the Exchange Offer, each Warrant holder had the opportunity to receive 0.18182 shares of WillScot Class A Common Stock, par value $0.0001 per share (“Common Stock”), for each Warrant tendered by the holder and exchanged pursuant to the Exchange Offer. As of the closing of the Exchange Offer on December 11, 2018, 45,131,827 outstanding Warrants were properly tendered and not withdrawn in the Exchange Offer. 45,031,827 of the Warrants tendered were public warrants, representing approximately 89% of the public warrants, and approximately 100,000 Warrants tendered were private warrant
DoubleVerify and InMobi Unite to Combat Mobile App Fraud11.12.2018 18:02 | Pressemelding
Partnership brings mobile app fraud prevention to advertisers globally NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced a partnership with InMobi, a global provider of enterprise platforms for marketers. As part of the partnership, DoubleVerify will provide always-on fraud filtering and measurement for mobile in-app advertising campaigns across the InMobi Exchange globally. The integration with InMobi covers pre-bid targeting for all InMobi Exchange impressions within the leading mobile in-app platform, as well as monitoring of post-bid fraud activity, such as spoofing – enabling InMobi to continuously refine the quality of its mobile ad inventory. “DV’s partnership with InMobi demonstrates our commitment to provide consistent, comprehensive quality coverage for global brand advertisers,” said Matt McLaughlin, COO at DoubleVerify. “With ad spend increasingly concentrated in
Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform11.12.2018 15:00 | Pressemelding
Groundbreaking multispectral data acquisition and network segmentation capabilities provide deeper OT network visibility and reduce risk for industrial enterprises and critical infrastructure providers NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network protection, today announced several significant enhancements to its award-winning Continuous Threat Detection product and technology integrations with several leading industrial automation, network infrastructure and cybersecurity providers. Already the industry’s most complete industrial control systems (ICS) cybersecurity platform, this release incorporates new functionality to provide even more “extreme” visibility into ICS networks and help industrial enterprises decrease the risk of a cyberattack. The latest release of Claroty Continuous Threat Detection provides a large number of significant enhancements including: Virtual Zones and OT Network Segmentation – an innovative approach
INN Launches Battery Metals Channel11.12.2018 15:00 | Pressemelding
The new battery metals channel is designed to educate investors with original content and expert insight on the growing battery metals industry. VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Investing News Network (INN) announces the launch of its battery metals channel. Responding to the growth and evolution of the battery metals market, this channel will host news, educational content and expert opinions on the lithium, cobalt, graphite, vanadium and manganese market segments. “INN has been a trusted source of information on the lithium, cobalt, graphite, vanadium and manganese markets for nearly a decade, and is excited to bring these sectors together under the battery metals umbrella,” said Nick Smith, CEO and publisher at INN. “Through connections with experts, our leading team of experienced writers creates original, insightful content on battery metals. INN educates investors in the industry by providing information they may never have access to on their own,” S
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer11.12.2018 14:30 | Pressemelding
KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the appointment of Hermann Russ, M.D., Ph.D., as its chief scientific officer, effective December 1, 2018. Dr. Russ invented the use of the company’s lead molecule GAL-101/MRZ-99030 for the treatment of degenerative diseases of the retina, including glaucoma and dry macular degeneration. He is also co-inventor of the so-called “trigger effect” of GAL-101/MRZ-99030 and GAL-102/MRZ 14042, which is a unique reverse prion-like self-propagation mechanism of action important for the company’s eye drop and oral treatment regimens. “We are gratified that Dr. Russ is joining the Galimedix management team, as his knowledge in the field, as well as intimate experience with the compound, have already proven instrumental in the development of our company to date,” commented Andrew Pearlman, Ph.D., CEO of Galimedix
Farmako: Cannabis distributor to become gateway to Europe11.12.2018 10:00 | Pressemelding
Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research and development FRANKFURT, Germany, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Frankfurt-based pharmaceutical company Farmako is a research-based pharmaceutical company that distributes medical cannabis. The company is active in all European markets that have created a legal basis for cannabinoid therapies. It is the first company for medical Cannabis pursue distribution licences in multiple European countries. Fort hat, it will rely on EU-GMP certified suppliers. The German market for medical cannabis is estimated at 19.1 million euros in 2018 and at 200 million Euros by 2019. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400. The number of patients for cannabinoid therapies in Germany has grown from
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom